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Abstract. The blood–brain barrier (BBB) is a complex functional barrier composed of endothelial cells,
pericytes, astrocytic endfeets and neuronal cells. This highly organized complex express a selective
permeability for molecules that bear, amongst other parameters, adequate molecular weight and
sufﬁcient liposolubility. Unfortunately, very few therapeutic agents currently available do cross the BBB
and enters the CNS. As the BBB limitation is more and more acknowledged, many innovative surgical
and pharmacological strategies have been developed to circumvent it. This review focuses particularly on
the osmotic opening of the BBB, a well-documented approach intended to breach the BBB. Since its
inception by Rapoport in 1972, pre-clinical studies have provided important information on the extent of
BBB permeation. Thanks to Neuwelt and colleagues, the osmotic opening of the BBB made its way to
the clinic. However, many questions remain as to the detailed physiology of the procedure, and its best
application to the clinic. Using different tools, amongst which MRI as a real-time in vivo characterization of
the BBB permeability and CNS delivery, we attempt to better deﬁne the osmotic BBB permeabilization
physiology. These ongoing studies are described, and data related to spatial and temporal distribution of a
molecule after osmotic BBB breaching, as well as the window of BBB permeabilization, are discussed. We
also summarize recent clinical series highlighting promising results in the application of this procedure to
maximize delivery of chemotherapy in the treatment of brain tumor patients.
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INTRODUCTION
Systemic treatment of many central nervous system
(CNS) diseases, such as brain tumors, is considerably
impaired by limited delivery of therapeutics. Poor CNS access
is mainly related to selective barriers that sequester the CNS
from the circulatory system (1). In 1885, Paul Ehrlich was the
ﬁrst to demonstrate experimentally that the brain is a
sanctuary site (2,3). In contrast to peripheral organs, he
observed a lack of CNS coloration after intravenous injection
of vital dyes. Almost 30 years later, Ehrlich’s student Edwin
Goldmann noticed the opposite phenomenon following
injection of these dyes in the cerebrospinal ﬂuid (CSF; 4).
The staining was then conﬁned to the CNS and peripheral
organs were exempted of any coloration, suggesting the
presence of a barrier between the CNS and the circulation.
Research endeavour that followed these pioneer works
ascribed this observation to the BBB. Located at the blood/
brain interface, this barrier represents the primary obstacle to
CNS penetration for blood circulating therapeutics (5).
The BBB is a complex functional barrier collectively
composed of endothelial cells, pericytes, astrocytic endfeets
and neuronal cells (6–9). This highly organized complex, also
known as the neurovascular unit, confers unique properties to
the CNS endothelium accounting for the selective permeabil-
ity of the BBB. Endothelium tight junctions, lack of fenestrae
and low pinocytic/endosomal transport prevent the diffusion
of hydrosoluble molecules across the BBB (10–12). More-
over, astrocytic endfeet conﬁguration practically seals CNS
vessels by covering nearly 99% of their external surface (13–
15). This peculiar organization of the BBB restrains passive
transport (non-receptor or non-carrier mediated transport) to
the CNS compartment from the blood.
To achieve CNS entry in the presence of an intact BBB,
a molecule must weight less than 180 Da and bears a
sufﬁcient liposolubility (16,17). The latter is deﬁned by an
optimal oil/water partition coefﬁcient value of 1.6 or by the
formation of less than eight to ten hydrogen bonds with
solvent water (18–20). These properties are the most decisive,
but the degree of ionization, plasma protein binding, local
cerebral blood ﬂow and afﬁnity for dedicated carriers can also
inﬂuence the BBB permeabilization (21). Unfortunately, very
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ones who do, CNS entry is not assured (22,23). In fact, highly
active efﬂux pumps, such as P-glycoprotein (P-gp), offers an
additional layer of protection to the CNS by expelling
harmful molecules back in the blood (24,25). As a conse-
quence, 98% of small molecules and the totality of large
molecular weight drugs are excluded from the CNS compart-
ment (19). The BBB thus regulates the fragile brain
homeostasis by strictly controlling the composition of the
CSF and extracellular ﬂuid compartment via entrance and
withdrawal of speciﬁc compounds at the blood–brain interface.
The Altered BBB in the Context of Brain Neoplasia
Although the integrity of the barrier is often compro-
mised within a tumor, this alteration in permeability is
variable and dependent on tumor type and size. Moreover,
it is extremely heterogeneous in a given lesion. Although the
BBB is frequently leaky in the center of malignant brain
tumors, the well-vascularized actively proliferating edge of
the tumor (the brain adjacent to tumor or BAT), has been
shown to have variable and complex barrier integrity (26).
Therefore, by steeply reducing the concentration of intrave-
nously administered chemotherapeutic agent at the periphery
of the tumor, this sink effect phenomenon is yet another
mechanism that can contribute to chemotherapy failure in
CNS neoplasm treatment.
Despite increasing recognition, this topic remains con-
siderably underdeveloped in the ﬁeld of neurosciences. More
so, it is said that if a pharmaceutical company decided to
develop a research program on the BBB, there would be few
BBB-trained scientists to hire, because less than 1% of U.S.
academic neuroscience programs emphasize BBB transport
biology (27).
Bypassing the BBB
In spite of the limitations imposed by the BBB, trans-
vascular delivery still represents, in our view, the ideal global
dissemination channel to the CNS. The extensiveness of the
cerebral vascular network insures a quick and global way to
reach the CNS, if the mechanisms collectively called BBB can
be bypassed (28–30).
Many innovative strategies have been developed to
circumvent the BBB in order to increase drug delivery to the
CNS. These approaches can be broadly classiﬁed under two
headings: surgical and pharmacological. Surgical approaches
typically involve a more invasive paradigm. Trans-nasal
delivery routes, and transcranial delivery, either via intracere-
bral implants or via convection enhanced delivery (CED), are
classiﬁed under this heading. Osmotic BBB disruption, which
involves placement of an intra-arterial catheter and general
anesthesia is also considered a surgical approach.
Pharmacological oriented strategies involve drug modiﬁ-
cation, pro-drug synthesis, and the use of pharmacological
agents to breach the BBB, such as bradykinin agonists, like
RMP-7. Other investigators are exploiting the presence of
dedicated carrier or receptor-mediated transport systems,
also classiﬁed as pharmacological-oriented strategy.
We elected to work with osmotic blood–brain barrier
disruption (BBBD), as this approach is already in clinical use
and provide a global hemispheric delivery paradigm (16).
However, by no means do we imply that it is the sole or the
best approach to gain access to the CNS. As a matter of fact,
our lab is also studying and developing pharmacological
approaches to breach the BBB.
OSMOTIC BLOOD BRAIN BARRIER DISRUPTION
In 1972, Rapoport et al. reported CNS tissue staining by
Evans Blue consequently to intra-arterial infusion of hyper-
tonic arabinose (26). Since Evans Blue, which binds to
albumin, is not expected to permeate through the intact
BBB, this observation suggested a BBB alteration by
hypertonic arabinose. The authors proposed that hypertonic
solutions increased BBB permeability by inducing the shrink-
age of cerebrovascular endothelial cells, thus producing a
disruption of inter-endothelial tight junctions (31,32). The
concept of osmotic BBBD was then introduced. Brightman
and coworkers later supported this hypothesis, as they
Fig. 1. Graphical sketch illustrating the hypothesis concerning the osmotic BBB modiﬁcation. The tight
junctions are shown a as devoid of any anatomic space between the endothelial cells. Moreover, multi-drug
resistance (MDR) gene products, such as the P-gp efﬂux pump, are also illustrated as they are integral to the
mechanism of the barrier. The osmotic BBBD procedure induces a retraction in the cell membrane, and a
physical opening b accompanied by a modiﬁcation of the Ca
2+ metabolism in the cell
167 Blood–Brain Barrier Disruption as CNS Delivery Strategysuccessfully visualized opened endothelial tight junctions with
electron miscroscopy after intra-carotid infusion of mannitol
in several species (32). In 1984, Dorovini-zis et al.a l s o
observed opened inter-endothelial tight junctions when
endothelial cell cultures were exposed to a hypertonic
solution (33). Although the precise mechanism of osmotic
BBBD is still debated, such works support the concept of
tight junctions physical disruption by shrinkage of CNS
endothelial cells (Fig. 1).
Besides arabinose, hyperosmolar solutions of lactamide,
saline, urea, radiographic contrast agents and mannitol can
be used to transiently breach the BBB (21). The latter is
commonly used for BBBD in both animals and humans since
its administration has been approved many years before the
implementation of this technique. Since its initial description,
the procedure has been used in preclinical and even clinical
studies (34–37).
In this review, we intend to present information in a
translational continuum, reﬂecting the knowledge acquired
on the procedure from the pre-clinical ﬁeld to the clinical
application of BBBD.
Preclinical Data
Different BBBD animal models have been described in
the literature, but the rat model is the most reported on,
because of its ease of use (38). In these animals, the
procedure is standardized, and has been described in detail
in numerous studies (39–41). Brieﬂy, after general anesthesia
and endotracheal intubation, the carotid complex is exposed,
and the external carotid artery is isolated. After incision and
retrograde cannulation of the artery with a PE-50 tubing, the
tip of the catheter is positioned near the carotid bifurcation.
The hypertonic solution of mannitol is then infused in a
retrograde fashion in the internal carotid artery, followed by
the administration of the therapeutic agent (42).
The work of different investigators suggested that the
anesthetic agents must be chosen carefully because their
hemodynamic effects can impact on the quality of the BBB
opening (43,44). We initiated our pre-clinical studies with
ketamine/xylazine, and had to design a modiﬁcation to the
model to circumvent the negative impact of ketamine on the
cerebral blood ﬂow that ultimately affected the extent of
BBBD (44). This was accomplished by simply isolating the
perfused hemisphere from the systemic circulation by apply-
ing a temporary vascular clip to the common carotid artery,
prior to the infusion of mannitol (Fig. 2). This prevented
backﬂow of mannitol in the cardiac chamber, and increased
the extent and reliability of the procedure (42).
Ultimately, however, propofol proved to be the anes-
thetic agent of choice as it improved both the efﬁciency and
consistency of the disruption procedure in animals (43). As
propofol is infused continuously (iv) and has a very short half-
life, it can be easily titrated, insuring a better control over
vital signs than with ketamine. More so, propofol is an
antiseizure medication and a cerebro-protectant, thus con-
ferring to this anesthetic the ideal proﬁle for the BBBD
procedure.
However, as the use of propofol translates in a better
delivery, the drawback we observed was an increase in
neurotoxicity with some co-administered chemotherapeutic
agents otherwise known to be safe when paired to other
anesthetics (45).
Pre-clinical Quantitative Studies
Albumin
Several factors can negatively impact the effectiveness of
the BBBD; hemodynamic variables, anesthetic agent and rate
of infusion of hypertonic solutions are but a few examples
(43,46). As a consequence, even repeated procedures in the
same individual or animal can lead to highly variable BBB
disruptions. It is thus paramount to monitor the extent of
BBB permeation for each procedure, if we wish to study the
actual inﬂuence in the intensity of delivery against different
outcome.
This can be accomplished in the clinic with the use of
a contrast-enhanced CT scan performed shortly after
BBBD. The magnitude of BBBD is then evaluated in a
semi-quantitative fashion, using visual scale (47). A similar
principle has been described by Rapoport in pre-clinical
studies, where the contrast-enhanced CT scan is substituted
by a macroscopic staining of the rat cerebrum using Evans
blue, a staining compound that binds the albumin (48,49).
The staining at the surface of the brain is evaluated against
an arbitrary staining scale, returning a qualitative evaluation
in the intensity of delivery (16,20;F i g .3). This approach is
inherently subjective and the reliability of the generated
results is therefore questionable. More so, the fact that the
Evans blue so tightly binds albumin is questioned nowadays.
This is obviously a critical issue on which the whole concept
is based. Another weakness of this approach arises from the
global superﬁcial evaluation, in that only the cortical surface
is surveyed; the deep structures are not visualized and no
data is gain on the topographic extent of delivery.
To overcome these shortcomings, we adapted an
approach based on albumin immunohistochemistry. This
concept has been exploited in the past by Vorbrodt et al.t o
study the dynamics of BBBD (50). These authors used
quantitative immunocytochemistry against albumin, fol-
Fig. 2. Surgical setup for BBBD. The carotid complex was exposed,
and the external carotid artery was ligated and incised. A PE50
tubing was inserted in a retrograde fashion, and was positioned just
above the bifurcation. The tubing was stabilized with a suture. Notice
the clip on the common carotid artery, used to prevent backﬂow
during mannitol infusion
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of their score was based on the square micrometer density of
gold particles, and was used to detail the dynamics in the
BBB permeabilization across different compartments. Thus
the image analysis was performed on electron micrographs
and did not allow a global estimation of delivery.
We designeda simple approach that allows theconstitution
of a precise data translating numerically the extent of delivery.
Brieﬂy, we conducted osmotic BBBD with mannitol in
adult male Fisher rats, with infusion rates ranging from 0.01 to
0.15 cc/s. Brains were subsequently harvested and brain slices
were processed for albumin immunochemistry, using a
rabbit polyclonal antibody against albumin in a dilution of
1/100. Biotinylated species-speciﬁc secondary antibody was
applied (1/100) followed by an avidin–biotin ampliﬁcation
and peroxidase development. Afterwards, brain slices were
digitized and ratios of stained pixels on total brain pixels
were calculated. Percentages of delivery were obtained
from these ratios (Fig. 4).
This data allows the production of a conservative
estimate on the extent of delivery, as albumin is a large pro-
tein. It is expressed as a percentage of the treated hemisphere
on a given coronal slice, and can also be used as a composite
score translating global delivery, by simply summating the
scores obtained on multiple contiguous slices. As the brain
samples are cut in a standardized fashion using a brain matrix,
the number of slices is always consistent, thus ensuring that
the composite score is reproducible. Its objectiveness should
help investigators to evaluate the impact of various surrogates
on the CNS delivery and thus contribute to a better com-
prehension and characterization of the BBBD process.
However, it has a signiﬁcant drawback; sacriﬁce of the test
Fig. 3. Whole brain and corresponding coronal slices of samples extracted from one
representative animal of each group exposed to different rates of mannitol infusion as
assessed by Evans blue staining. A sequential increment in blue discoloration is obvious,
peaking at 0.15 cc/s
Fig. 4. Description of the steps involved in the calculation of the intensity of delivery ratio used in this study. a The albumin
immunocytochemistry source image, displaying discolored areas in the treated hemisphere. b The image has been analyzed
to identify pixels above a ﬁxed threshold corresponding to the immunocytochemistry staining. These pixels are retained as
the red overlay. c After having deﬁned the pixel area of each hemisphere (green overlay is left hemisphere, whereas blue
overlay is right hemisphere), the red overlay has been added to the image for ﬁnal analysis. Results are expressed as number
of stained pixels (red overlay) as a fraction (%) of the treated (right) hemisphere (blue overlay). Results might also have
been presented as the fraction of stained pixels (red overlay) over the entire slice area (green+blue overlays)
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study over time. Hence, we are currently working on a
different investigational approach allowing real time in vivo
quantiﬁcation of the BBB permeability and CNS delivery
with MRI technology.
MRI Quantification of BBB Permeability
To palliate this lack of dynamic studies in the BBBD
process, we have designed a methodology allowing osmotic
BBBD to be conducted directly in the animal MRI gantry,
thus permitting the acquisition of images dynamically before,
during and after the procedure. This setup allows us to study
the distribution of contrast agents of different molecular
weight, to estimate brain exposure against several surrogates
following the osmotic BBBD, and to estimate the window of
barrier opening.
To evaluate the distribution of Gd-DTPA, a low molecular
weight contrast agent (0.9 KDa) within the brain of animals,
MRI signal intensity was analyzed in several regions of interest
(ROI) scattered across different areas of the brain over time.
Initial results highlight the heterogeneity in the CNS penetra-
tion,andthesubsequentdiffusionofcontrastagentfromanarea
representing the cleft between the brainstem and the cerebral
hemisphere (Fig. 5). This area was identiﬁed as consistently
presenting the largest exposure to Gd-DTPA after BBBD. The
Fig. 5. An axial T1 enhanced cut, at the posterior aspect of the brain of a Wistar rat, prior (a) and after (b)
BBBD. The arrow depicts the cleft area presenting the most intense increase in Gd-DTPA. It is from this
area that a diffusion wave is observed
Fig. 6. Graphic depicting the Magnevist (Gd-DTPA) concentration over time in the
disrupted hemisphere (right) and the non disrupted hemisphere (left) in T1 MRI sequence
acquisition. Notice the pronounced signal drop at time 3 min, immediately after BBBD,
translating the increase in water content caused by the BBBD
170 Bellavance, Blanchette and Fortindynamics in the exposure of the brain to Gd-DTPA over time
highlighted two different mechanisms by which the procedure
increases BBB permeability: (1) a direct permeabilization of
the BBB, (2) and a diffusion of the contrast agent within the
brain from the area described above (Fig. 5).
The ﬁrst phenomenon is a diffuse process of short
duration observed in the whole treated hemisphere, and
accounts for the initial T1 MRI signal drop, as water content
is increased in the extracellular space (Fig. 6). The second
mechanism involves a diffusion process in the interstitial
compartment, and is directly affected by molecular size of the
compound under study. This mechanism results in a delayed
and broader distribution of the signal that eventually reach
the contralateral hemisphere, producing a maximal exposure
to the studied molecule much later. As an example, this delay
is 66 min for Gd-DTPA. Interestingly, when studying mole-
cules of a higher molecular weight, the distribution volume is
more limited, as the large size of the molecule prevents free
diffusion through CNS extracellular spaces. As an illustration
of this, high molecular weight contrast agents such as
Gadomer, a 17 kDa synthetic dendrimer linked to paramag-
netic Gadolinium molecules, hardly reach the opposite hemi-
sphere (Blanchette et al., unpublished data).
To quantify brain exposure, initial brain tissue MRI
signal intensity was recorded and subsequent signals mea-
sured during and after the BBBD were correlated to contrast
agent concentrations by mathematical manipulations. Brain
exposure can thus be assessed as a function of the amount of
contrast agent in a given brain compartment (Fig. 7). As
expected, overall brain parenchyma is more exposed to Gd-
DTPA than Gadomer because of its lower molecular weight,
allowing a wider volume of distribution. As a consequence,
Gd-DTPA is also washed out more rapidly from the brain
compartment than Gadomer. In fact, the latter appears to
remain trapped in the brain for a longer period. These results
suggest that both volume of distribution and persistence of a
given molecule in the CNS is related to its molecular weight.
Therefore, an equilibrium between these two parameters is
the key to an optimal brain exposition.
To deﬁne the duration of BBB opening following the
osmotic disruption, delayed administration of Gadomer
(17 kDa) is currently carried at different times after the osmotic
Fig. 7. An axial T1 Gd-DTPA enhanced MRI immediately after BBBD is analyzed using an exposition map
translating the area under the curve (AUC). In this animal in which the intensity of the BBBD was
moderate at best, the right hemisphere present a slight change in signal intensity (a). A map of the area
under the curve (AUC) produced by the permeabilization procedure is presented in (b). Mathematical
function extracted for a single pixel in the white matter of the right hemisphere. The increase in intensity is
studied over time (c). Mathematical function extracted for a single pixel in the subependymal region of the
right hemisphere (d). This area consistently depicts the most intense signal variation after osmotic BBBD
171 Blood–Brain Barrier Disruption as CNS Delivery StrategyBBBD procedure. Data obtained so far suggests that the BBB
is still permeable to big molecules such as Gadomer up to 6 h
after the osmotic BBBD (Fig. 8).
We are also in the process of studying the impact of
BBBD on the activity of different efﬂux pumps, and on the
brain metabolism with 18-FDG.
CLINICAL STUDIES
Thanks to the pioneering work of dedicated teams, the
BBBD procedure has made its way to the clinic, and it has
been extensively studied.
Neuwelt and his group conducted the ﬁrst phase I clinical
studies on osmotic opening of the blood–brain barrier,
beginning in 1979 (16,36). Ever since, this group has been
leading the clinical research effort on BBBD, joined by other
institutions under the umbrella of the international BBBD
consortium. A brief description of the clinical procedure will
be detailed, followed by results obtained in clinical studies in
the treatment of brain tumors.
Description of the Clinical BBBD Procedure
As general anesthesia is required, the osmotic opening of
the BBB is accomplished in the operating room or in the
angiography suite.
The human cerebral arterial system is organized in such a
way that there basically are four major arteries responsible for
the brain irrigation. The vascular anatomy can be variable from
oneindividual to another, andthus the precise anatomy must be
determined during the ﬁrst treatment session by a formal
cerebral angiography. The nature of the procedure, by produc-
ing a vasogenic edema in the treated vascular distribution, do
not allow for disruption of more than one vascular territory in a
singletreatmentsession.Thisimpliesthatifalesioncoversmore
than one vascular distribution, or if there are multiple lesions,
the treatment will be delivered in different distribution from
cycle to cycle, to cover all relevant cerebrum territory.
Since hemodynamic factors impact on the degree of
disruption, every attempt is made to keep heart rate and
systemic pressure stable and above threshold values (estab-
lished for each patient) during the general anesthesia (36,51).
After general anesthesia, the technique involves the
following steps:
1. Selective catheterization via percutaneous transfe-
moral puncture of left internal carotid artery, right
internal carotid artery, left vertebral artery or right
vertebral artery. The tip of the catheter is positioned
at the C2–C3 vertebral level in the carotid, or at the
C6–C7 vertebral level in the vertebral artery.
2. Determination of rate of infusion of mannitol by
iodinated contrast injection and ﬂuoroscopy, as the
lowest infusion rate in which there is retrograde ﬂow
from the arterial catheter. The volume of mannitol
infused will be the rate determined in cc/s×30 s.
(usually between 4 to 10 cc/s in carotid circulation, and
between 4 to 8 cc/s in vertebral circulation). The
ultimate goal is to ﬁll the entire vascular compartment
in a given vessel distribution, without producing back-
ﬂow of mannitol in the parent vessel.
3. The osmotic disruption is a physiologically stressful
procedure. It can induce focal seizures in 5% of proce-
dures (51). It can also trigger a vaso-vagal response
Fig. 8. Graphic depicting the Gadomer concentration over time in the disrupted
hemisphere (right) in a selected region of interest of the frontal lobe. The ﬁrst
administration of Gadomer (600 μl of a 0.1429 mmol/ml solution at a rate of 500 μl/min)
was accomplished 3 min after BBBD. A signiﬁcant increase in the concentration was
observed. The infusion was repeated at 150, 300 and 360 min after BBBD. Notice small
increments in concentration translating the residual permeability breach of the barrier that
is still open at 360 min
172 Bellavance, Blanchette and Fortinwith bradycardia and hypotension. In order to prevent
the occurrence of these adverse effects, different
medications are administered just prior to the disrup-
tion to stabilize heart rate, pressure, and to produce
neuro-protection.
4. Osmotic disruption of the blood brain barrier is
accomplished by infusing mannitol 25% in the previ-
ously catheterized artery at the previously deﬁned
rate.
& During the infusion, interesting signs can be observed.
The medial aspect of the forefront ipsilateral to the
side of the infusion undergoes a whitish discoloration
produced by the washout of blood from the ethmoidal
branches, arteries known to connect the intracranial
circulation to the extra cranial circulation. Bilateral
pupillary dilatation can also be observed during the
mannitol infusion. This is followed by a brief period of
tachycardia and systemic hypertension.
5. Intra-arterial contrast is infused to conﬁrm catheter
position and rule out arterial injury post-disruption.
6. Infusion of the therapeutic molecule intra-arterially in
the disrupted circulation. The concentration of the
solution and the rate of infusion are critical factors
when infusing intra-arterial solutions in avoiding
neurotoxicity. The phenomenon of streaming deﬁnes
an inhomogeneous distribution of the administered
solution because of poor mixing at the infusion site. It
is directly related to the Reynold number, a crucial
parameter in ﬂuid dynamics that predicts the transi-
tion from streamlined to turbulent ﬂow (52). In the
equation leading to the Reynold number, the density
and viscosity of ﬂuid, lumen diameter of the infused
vessels and velocity of ﬂow are all important determi-
nants to control in order to avoid streaming (53).
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ery room, where his neurological status and state of con-
sciousness will regularly be evaluated until full recovery.
If the degree of BBBD opening needs to be assessed, a
standard dose of IV non-ionic contrast bolus can be adminis-
tered 5 min after the mannitol infusion. At the end of the
procedure, before proceeding to the recovery room, the
patient is taken to the CT scan suit.
Contraindications to the BBBD Procedure
The blood–brain barrier disruption procedure induces a
transient rise in intra-cranial pressure (ICP) (baselines 3 to
9c mH 2O to peaks of 16–23 cm at 30 min post disruption).
This transient rise in ICP has been shown to correlate with a
1.5% increase in brain ﬂuid content (20,54). In pre-clinical
studies, this transient increase in ICP was not associated with
any clinical sequelae (20). It illustrates however the rationale
behind the very ﬁrst contraindication of osmotic BBBD: the
presence of a signiﬁcant mass effect. The deﬁnition of mass
effect is somewhat arbitrary, but we uses standard clinical
criteria to exclude patients deemed at risk.
Other contraindications to the procedure are also present,
and include: evidence of spinal cord block from tumor mass,
signiﬁcant increased risk for general anesthesia and signiﬁcant
intra-arterial vascular pathologies.
Adverse Effects
In a seminal paper published by McAllister et al., the
effect of the procedure combined to chemotherapy infusion
(methotrexate) on neurocognitive function was evaluated in
long term survivors from the procedure. Contrary to numerous
established treatment modalities (e.g. cerebral radiotherapy),
the BBBD procedure was not associated with any decline in
formal neurocognitive assessment (55).
Adverse effects can nevertheless occur, and for ease of
discussion, are stratiﬁed in two groups:
1- Catheter related complications
& Asymptomatic subintimal tear during catheterization
(incidence 5%)
& Signiﬁcant groin hematoma post catheterization
(incidence 0.5%)
& Parent vessel thrombosis, as experienced in two of
our patients (incidence 0.5%). This complication can
produce long term neurological disability related to
the vascular distribution involved. Fortunately, the
occurrence of this complication did not translate in
clinical repercussion in our patients.
2- Disruption related complications
& Seizures (incidence 5%). Seizures are typically focal,
and are immediately treated with IV thiopental and/
or IV Diazepam. This is typically a procedure related
event.
& Temporaryobtundationand/orincreaseinneurological
symptoms (incidence 2.5%). Complete recovery is the
norm, and it typically last less than 48 h. This adverse
effect is associated with an excellent disruption.
& Brain herniation. Obviously, the most serious compli-
cation. One patient expired from this complication
(incidence 0.3%). It is the only mortality event related
to the procedure in 300 patients that underwent a total
of more than 3,000 procedures (51).
Doolittle et al. thus concluded that the procedure was
safe, when performed in a standardized multicenter con-
trolled setting (51).
Clinical Results Obtained with the BBBD Procedure,
in the Treatment of Brain Tumors
Clinical results observed with the procedure will brieﬂy
be detailed below. However, before we initiate this discussion,
a few key points ﬁrst need to be addressed. Most clinical
studies on BBBD have been conducted in patients with brain
tumors, to increase delivery of chemotherapy. Some of these
tumors, such as malignant astrocytomas, are notoriously
chemoresistant, and as such, are not as likely to respond to
chemotherapy as other type of cancers. Thus, two distinct
factors are at play, difﬁcult to segregate from each other in
outcome studies: the delivery intensity, and chemosensitivity
of the tumor. This limitation must be recognized when
analyzing results from these studies. A negative study could
be related to the choice of a poorly active therapeutic agent,
even though this agent was adequately delivered to its target.
173 Blood–Brain Barrier Disruption as CNS Delivery StrategyWhen reviewing the clinical results on BBBD, all variables
involved must be considered and adequately weighted against
the surrogates under study.
In an attempt to decrease the number of variables
involved, to nullify the choice of the chemotherapy agent and
to speciﬁcally isolate the impact of delivery in the treatment of
brain tumors, Kraemer et al. adopted an interesting approach
(56). These authors studied the intensity of delivery against
tumor response and survival in primary CNS lymphoma, a
notoriously chemosensitive CNS tumor nonetheless depicting a
poor outcome. Two surrogate measures of total dose intensity
were used in the design of a delivery score: the number of
disruption procedures over the treatment and a weighted
quality of disruption score. In this study, the extent of the
increase in permeability produced by the procedure correlated
with long term survival in a population of patients treated
Fig. 9. A 69 year old woman was diagnosed with poorly differentiated ovarian adenocarcinoma in May 2001,
at which time she underwent extensive abdominal and gynecologic surgery, followed by six cycles of taxol/
carboplatin. She presented a seizure in May 2002, and a metastatic lesion was identiﬁed in the right parietal
region. She underwent a craniotomy for tumor resection, followed by eight cycles of the carboplatin regimen
in conjunction with BBBD. She was considered in complete response (CR) after two cycles, and that
condition was maintained until December 2005, when she relapsed in the right temporal lobe (a). BBBD
treatments were resumed, and she was considered in CR after three cycles (b)
Fig. 10. Kaplan–Meier survival curve (days) for the global group of metastasis patients,
from study entry to death
174 Bellavance, Blanchette and Fortinwith the BBBD procedure combined with intra-arterial
methotrexate infusion, emphasizing the importance of delivery
on the patient’s outcome (49).
The procedure has been applied in the treatment of
different brain tumor types. Williams et al. reported on the
use of BBBD in conjunction with a regimen composed of
intra-arterial carboplatin and intra-venous etoposide in 34
patients with various histologies (57). Of these 34 patients, 22
had measurable disease, and nine radiographic responses
(50% or more decrease in enhancing tumors) were observed
in these patients. Carboplatin and etoposide delivered in con-
junction to BBBD was considered an active regimen in the
treatment of malignant astrocytomas and showed dramatic
responses in primitive neuroectodermal tumors and CNS
lymphoma.Additionally,thedurabilityofresponsesinpatients
with disseminated CNS germ cell tumors is encouraging.
Kreamer et al. reported on the use of a similar protocol,
using, in addition to the carboplatin and etoposide, a pre-
disruption dose of i.v. cyclophosphamide in a series of 41
malignant astrocytoma patients (37). In this series, 28 patients
were exposed to the BBBD treatment, whereas 13 patients
received intra-arterial (IA) chemotherapy only. Although
treatment modality (BBBD versus IA) scored as a highly
signiﬁcant variable both in uni- and multivariate analysis (p=
0.0113), and thus BBBD patients survived signiﬁcantly longer
than IA patients, bias cannot be accounted for in this type of
uncontrolled study. A median survival time of 90 weeks for
the BBBD group was observed, compared to 50 weeks for the
IA group.
The Centre Hospitalier Universitaire de Sherbrooke
(CHUS) neuro-oncology group joined the consortium in
2000 and has recently reported results with the BBBD pro-
cedure combined with the administration of a carboplatin-
based tri-drug regimen (58). We observed a prolonged
median survival of 32.2 months in the treatment of glioma,
more than double the reported median survivals of 9 to
14 months with standard therapeutic modalities (59–62). We
also recently reported our clinical data on brain metastasis
(53). We observed a spectacular improvement in median
survival for brain metastasis from ovarian carcinoma, lympho-
mas and lung carcinoma. Our series depicted median survival
of 24 months for ovarian carcinoma, 16 months for systemic
lymphomas and 13 months for lung carcinoma, compared to
reported median survival of 12 months, 3 months and 7 months
respectively for ovarian, lymphoma and lung brain metastasis
patient series (Figs. 9 and 10).
Recently, Hall et al. reported the experience of the
consortium with diffuse pontine gliomas, a tumor type
bearing a particularly poor prognosis, and typically affecting
young patients (63). In this small series of eight patients
exposed to BBBD and carboplatin or methotrexate, a median
time to progression of 15 months, and a median survival of
27 months were deemed promising. In this type of tumor,
survival beyond 2 years is exceptional, and it really is the
ﬁrst time that a chemotherapy trial is reported to impact
outcome (64).
All in all, these results clearly hint at an improvement in
brain tumor patient’s outcome. Ultimately, the real question
is whether or not the procedure can impact tumor response
and patients survival. To ascertain this query thoroughly,
randomized phase III studies would need to be conducted. As
only a few centers are offering the BBBD procedure, and as
these tumors are not prevalent diseases, these studies are
particularly difﬁcult to put together. However, recent results
showing major improvement in the survival of patients
affected by different types of brain tumors and treated via
the BBBD approach should prompt major oncology organ-
izations to consider osmotic BBBD as a viable therapeutic
option, even though the logistic of the procedure is complex,
and setup multi-center randomized trials.
CONCLUSION
The blood–brain barrier can no longer be ignored as a
factor greatly limiting the entry of therapeutics in the CNS.
According to Pardridge, over 98% of small molecules and
close to 100% of large molecules do not cross the BBB (19).
In neuro-oncology, clinical trials on brain tumor treatment are
still designed with molecules that do not cross the BBB (e.g.
vincristine, taxol). The peculiarities imposed by the BBB in
the treatment of CNS diseases can no longer be ignored, and
the delivery issue needs to be addressed appropriately. Less
than 1% of pharmaceutical companies actually have a BBB
drug targeting effort. The BBBD strategy initially proposed
more than 3 decades ago has come a long way, venturing in the
realm of clinical studies. However, its widespread acceptance
has been hampered by many factors: the difﬁculty in setting
teams dedicated to perform these procedures, the relative
paucity of brain tumors, the difﬁculty of putting together
randomized studies are but a few factors. However, concerted
effort such as the international BBB consortium will allow the
design of better multi-center trials eventually powered to
answer whether or not this approach is worthwhile in the
treatment of different CNS pathologies. As the clinical results
obtained in the treatment of malignant gliomas and brain
metastasis (representing the bulk of brain cancers) overall
remains poor with traditional treatments, and very few major
breakthroughs have been reported in the last decades despite
active clinical research, clinical investigators tend to adopt a
more open-minded approach toward alternative treatment
strategies emphasizing CNS delivery. The promising results
obtained in trials published on BBBD in the last decade will
allow a better accrual of patients in clinical studies. However,
promising results are just that, promising results, until
randomized clinical studies can be put together and show a
clear advantage of such an invasive technique on patient’s
survival. We are about to open such a randomized study in
patients with oat cell carcinoma metastatic to the brain.
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